Albert Pares, MD, PhD - Hospital Clinic, University of Barcelona - Professor

Albert Pares

MD, PhD

Hospital Clinic, University of Barcelona

Professor

Barcelona | Spain

Main Specialties: Critical Care Medicine, Gastroenterology, Hepatology, Internal Medicine

Additional Specialties: Internal Medicine, Hepatology

ORCID logohttps://orcid.org/0000-0002-5413-9687


Top Author

Albert Pares, MD, PhD - Hospital Clinic, University of Barcelona - Professor

Albert Pares

MD, PhD

Introduction

Dr. Albert Parés is Professor of Medicine at the University of Barcelona and Senior Consultant of the Liver Unit at the Hospital Clinic in Barcelona (Spain). Doctor Parés received his MD from the University of Barcelona Medical School. He was a resident in Internal Medicine and Gastroenterology at the Hospital Clínic, and he is specialist in both fields. He is specialist in Critical Care Medicine as well. During a 1991-92 sabbatical from Hospital Clínic he was a Visiting Professor at the Johns Hopkins School of Medicine in Baltimore, USA, in the laboratory of Dr. Esteban Mezey.
Doctor Parés’s interests are in cholestatic liver diseases in adults, particularly primary biliary cholangitis and primary sclerosing cholangitis as well as autoimmune hepatitis and alcoholic liver disease. The focus of his research has been in these fields, and he is more recently addressed to the consequences of chronic cholestasis mainly pruritus and metabolic bone disease. He has published numerous research papers in the top Gastroenterology and Hepatology journals and authored over 90 book chapters and reviews. Moreover, Dr. Parés has been in the editorial board of Liver and Journal of Hepatology, and now serves on the editorial board of World Journal of Gastroenterology, Clinics and Research in Hepatology and Gastroenterology, Gastroenterología y Hepatología, Revista Española de Enfermedades Digestivas and Medicina Clinica. Among other activities, he has served as member of the National Accreditation Commission for professors of the University of the National Agency for the Evaluation of Quality and Accreditation (ANECA), and since 2010 he is member of the International Committee that awards the "Adolf Windaus Prize" to an outstanding researcher in the field of bile acids.

Primary Affiliation: Hospital Clinic, University of Barcelona - Barcelona , Spain

Specialties:

Additional Specialties:


View Albert Pares’s Resume / CV

Metrics

Number of Publications

283

Publications

Number of Profile Views

811

Profile Views

Number of Article Reads

1170

Reads

Number of PubMed Central Citations

1072

PubMed Central Citations

Education

Jan 1974
University of Barcelona
M.D.
Jan 1974
University of Barcelona
M.D.

Experience

University of Barcelona
Professor of Medicine
Hospital Clinic/University of Barcelona
Senior Consultant

Top co-authors

Albert Pares
Albert Pares

Hospital Clinic, University of Barcelona

57
Pietro Invernizzi
Pietro Invernizzi

Center for Autoimmune Liver Diseases

16
Raoul Poupon
Raoul Poupon

Université Pierre et Marie Curie

15
Ulrich Beuers
Ulrich Beuers

University of Amsterdam

12
Pilar Peris
Pilar Peris

University of Barcelona

11
Juan Rodes
Juan Rodes

Hospital Clínic

10
Annarosa Floreani
Annarosa Floreani

University of Padova

10
Keith Lindor
Keith Lindor

Mayo Clinic

9
Ana Monegal
Ana Monegal

University of Barcelona

9

Publications

283Publications

1170Reads

1072PubMed Central Citations

Primary biliary cholangitis.

Authors:
Albert Parés

Med Clin (Barc) 2018 Sep 9;151(6):242-249. Epub 2018 Mar 9.

Unidad de Hepatología, Hospital Clinic, Universidad de Barcelona, IDIBAPS, CIBERehd, Barcelona, España. Electronic address:

View Article
September 2018
3 Reads
1.250 Impact Factor

Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis.

Gut 2018 08 4;67(8):1517-1524. Epub 2017 Aug 4.

Department of Gastroenterology and Hepatology, University of Groningen and University Medical Centre Groningen, Groningen, The Netherlands.

View Article
August 2018
54 Reads
2 PubMed Central Citations(source)
14.660 Impact Factor

Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.

Clin Res Hepatol Gastroenterol 2018 Aug 9. Epub 2018 Aug 9.

Hepatology department, reference center for inflammatory biliary diseases and autoimmune hepatitis, Saint-Antoine Hospital, Assistance publique-Hôpitaux de Paris, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France; INSERM, Sorbonne université, centre de recherche Saint-Antoine (CRSA), faculté de médecine, site Saint-Antoine, 27, rue de Chaligny, 75012 Paris, France. Electronic address:

View Article
August 2018
3 Reads
1.980 Impact Factor

Osteoporosis in chronic liver disease.

Liver Int 2018 May 25;38(5):776-785. Epub 2018 Mar 25.

Liver Unit, Hospital Clínic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain.

View Article
May 2018
12 Reads
4.850 Impact Factor

Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease.

Nat Genet 2017 Feb 19;49(2):269-273. Epub 2016 Dec 19.

Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.

View Article
February 2017
45 Reads
12 PubMed Central Citations(source)
29.350 Impact Factor

Thyroid Dysfunction in Primary Biliary Cholangitis: A Comparative Study at Two European Centers.

Am J Gastroenterol 2017 01 25;112(1):114-119. Epub 2016 Oct 25.

Liver Unit, Hospital Clinic-IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain.

View Article
January 2017
21 Reads
1 PubMed Central Citation(source)
10.760 Impact Factor

Sclerostin Expression in Bile Ducts of Patients With Chronic Cholestasis May Influence the Bone Disease in Primary Biliary Cirrhosis.

J Bone Miner Res 2016 09 22;31(9):1725-33. Epub 2016 Apr 22.

Center for Biomedical Research Network in Hepatic and Digestive Diseases (CIBERehd), Hospital Clínic, Barcelona, Spain.

View Article
September 2016
37 Reads
3 PubMed Central Citations(source)
6.830 Impact Factor

Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid.

Authors:
Albert Parés

Dig Dis 2015 7;33 Suppl 2:125-33. Epub 2015 Dec 7.

View Article
July 2016
18 Reads
2 PubMed Central Citations(source)
1.830 Impact Factor

Preface.

Dig Dis 2015 7;33 Suppl 2. Epub 2015 Dec 7.

View Article
July 2016
6 Reads
1.830 Impact Factor

Enteroendocrine cells are a potential source of serum autotaxin in men.

Biochim Biophys Acta 2016 04 14;1862(4):696-704. Epub 2016 Jan 14.

Tytgat Institute for Liver and Intestinal Research, Department of Gastroenterology and Hepatology, Academic Medical Centre, Amsterdam, The Netherlands. Electronic address:

View Article
April 2016
9 Reads
1 PubMed Central Citation(source)

Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists.

Hepatology 2016 Feb 26;63(2):644-59. Epub 2015 Nov 26.

National Institute for Health Research (NIHR), Birmingham Liver Biomedical Research Unit (BRU), and Center for Liver Research, University of Birmingham, Birmingham, United Kingdom.

View Article
February 2016
17 Reads
9 PubMed Central Citations(source)
11.050 Impact Factor

Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study.

Gut 2016 Feb 7;65(2):321-9. Epub 2015 Jan 7.

National Institute for Health Research (NIHR) Birmingham Liver Biomedical Research Unit (BRU) and Centre for Liver Research, University of Birmingham, Birmingham, UK Liver Unit, Queen Elizabeth Hospital, Birmingham, UK.

View Article
February 2016
25 Reads
16 PubMed Central Citations(source)
14.660 Impact Factor

Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis'.

Gastroenterology 2015 Nov 15;149(6):1627-9. Epub 2015 Sep 15.

Reference Center for Inflammatory Biliary Diseases, Service d'Hépatologie, Saint-Antoine Hospital, Paris, France.

View Article
November 2015
12 Reads
13 PubMed Central Citations(source)
16.720 Impact Factor

Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'.

J Hepatol 2015 Nov 15;63(5):1285-7. Epub 2015 Sep 15.

Reference Center for Inflammatory Biliary Diseases, Service d'Hépatologie, Saint-Antoine Hospital, Paris, France.

View Article
November 2015
12 Reads
8 PubMed Central Citations(source)
11.340 Impact Factor

Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'.

Hepatology 2015 Nov 15;62(5):1620-2. Epub 2015 Sep 15.

Reference Center for Inflammatory Biliary Diseases, Service d'Hépatologie, Saint-Antoine Hospital, Paris, France.

View Article
November 2015
7 Reads
20 PubMed Central Citations(source)
11.050 Impact Factor

Changing Nomenclature for PBC: From 'Cirrhosis' to 'Cholangitis'.

Am J Gastroenterol 2015 Nov 29;110(11):1536-8. Epub 2015 Sep 29.

Reference Center for Inflammatory Biliary Diseases, Service d'Hépatologie, Saint-Antoine Hospital, Paris, France.

View Article
November 2015
29 Reads
5 PubMed Central Citations(source)
10.760 Impact Factor

Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis'.

Gut 2015 Nov 14;64(11):1671-2. Epub 2015 Sep 14.

Service d'Hépatologie, Reference Center for Inflammatory Biliary Diseases, Saint-Antoine Hospital, Paris, France.

View Article
November 2015
8 Reads
4 PubMed Central Citations(source)
14.660 Impact Factor

Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'.

Dig Liver Dis 2015 Nov 26;47(11):924-6. Epub 2015 Sep 26.

Reference Center for Inflammatory Biliary Diseases, Service d'Hépatologie, Saint-Antoine Hospital, Paris, France.

View Article
November 2015
11 Reads
5 PubMed Central Citations(source)
2.960 Impact Factor

Histone deacetylase 4 promotes cholestatic liver injury in the absence of prohibitin-1.

Hepatology 2015 Oct 31;62(4):1237-48. Epub 2015 Jul 31.

CIC bioGUNE, Metabolomics Unit, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Bizkaia, Spain.

View Article
October 2015
21 Reads
4 PubMed Central Citations(source)
11.050 Impact Factor

Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'.

Clin Res Hepatol Gastroenterol 2015 Oct;39(5):e57-9

Reference Center for Inflammatory Biliary Diseases, Service d'Hépatologie, Saint-Antoine Hospital, Paris, France.

View Article
October 2015
7 Reads
4 PubMed Central Citations(source)
1.980 Impact Factor

Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis.

Hepatology 2015 Jul 28;62(1):188-97. Epub 2015 Apr 28.

Norwegian PSC Research Center, Department of Transplantation Medicine, Division of Cancer Medicine, Surgery and Transplantation, Oslo University Hospital Rikshospitalet, Oslo, Norway.

View Article
July 2015
10 Reads
8 PubMed Central Citations(source)
11.050 Impact Factor

Extrahepatic malignancies in primary biliary cirrhosis: a comparative study at two European centers.

Clin Rev Allergy Immunol 2015 Jun;48(2-3):254-62

Department of Surgery, Oncology and Gastroenterology, University of Padova, Via Giustiniani, 2, Padova, Italy,

View Article
June 2015
15 Reads
3 PubMed Central Citations(source)
5.460 Impact Factor

TRAIL-producing NK cells contribute to liver injury and related fibrogenesis in the context of GNMT deficiency.

Lab Invest 2015 Feb 22;95(2):223-36. Epub 2014 Dec 22.

1] Department of Metabolomics, CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Derio, Spain [2] Ikerbasque, Basque Foundation for Science, Bilbao, Spain.

View Article
February 2015
35 Reads
6 PubMed Central Citations(source)
3.680 Impact Factor

Ursodeoxycholic acid decreases bilirubin-induced osteoblast apoptosis.

Eur J Clin Invest 2014 Dec 9;44(12):1206-14. Epub 2014 Nov 9.

Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain; Metabolic Bone Diseases Unit, Department of Rheumatology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain; Liver Unit, Digestive Diseases Institute, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.

View Article
December 2014
24 Reads
3 PubMed Central Citations(source)
2.730 Impact Factor

Old and novel therapies for primary biliary cirrhosis.

Authors:
Albert Parés

Semin Liver Dis 2014 Aug 24;34(3):341-51. Epub 2014 Jul 24.

Department of Medicine, University of Barcelona, Liver Unit, Hospital Clínic, IDIBAPS,CIBERehd, Barcelona, Spain.

View Article
August 2014
18 Reads
3 PubMed Central Citations(source)
4.950 Impact Factor

Extracorporeal liver support in severe alcoholic hepatitis.

World J Gastroenterol 2014 Jul;20(25):8011-7

Albert Parés, Antoni Mas, Liver Unit, Hospital Clínic, University of Barcelona, IDIBAPS, CIBERehd, 08036 Barcelona, Spain.

View Article
July 2014
5 Reads
1 PubMed Central Citation(source)
2.370 Impact Factor

Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid.

Liver Int 2014 Feb 2;34(2):197-203. Epub 2013 Sep 2.

Liver Unit, Hospital Clínic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain.

View Article
February 2014
21 Reads
13 PubMed Central Citations(source)
4.850 Impact Factor

Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis.

Hepatology 2013 Dec 29;58(6):2070-8. Epub 2013 Oct 29.

Metabolic Bone Diseases Unit, Service of Rheumatology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, CIBERehd, Barcelona, Spain.

View Article
December 2013
13 Reads
7 PubMed Central Citations(source)
11.050 Impact Factor

Hepatotoxicity associated with glucosamine and chondroitin sulfate in patients with chronic liver disease.

World J Gastroenterol 2013 Aug;19(32):5381-4

Liver Unit, Institute of Digestive and Metabolic Diseases, Hospital Clínic, 08036 Barcelona, Spain.

View Article
August 2013
9 Reads
3 PubMed Central Citations(source)
2.370 Impact Factor

Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells.

Liver Int 2013 Aug 7;33(7):1029-38. Epub 2013 Apr 7.

Centro de Investigación Biomédica en Red, University of Barcelona, Barcelona, Spain.

View Article
August 2013
5 Reads
4 PubMed Central Citations(source)
4.850 Impact Factor

Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis.

Nat Genet 2013 Jun 21;45(6):670-5. Epub 2013 Apr 21.

Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.

View Article
June 2013
32 Reads
88 PubMed Central Citations(source)
29.350 Impact Factor

Tuberculosis is not a risk factor for primary biliary cirrhosis: a review of the literature.

Tuberc Res Treat 2012 30;2012:218183. Epub 2012 Oct 30.

Institute of Liver Studies, King's College Hospital and Division of Transplantation Immunology and Mucosal Biology, School of Medicine, King's College London, London SE5 9RS, UK.

View Article
December 2012
9 Reads

[Osteoporosis in liver cirrhosis].

Gastroenterol Hepatol 2012 Jun-Jul;35(6):411-20. Epub 2012 Apr 5.

Servicio de Reumatología, Unidad de Hepatología, Centro de Investigación Biomédica en Red de enfermedades hepáticas y digestivas, Insititut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Universidad de Barcelona, España.

View Article
November 2012
13 Reads
0.830 Impact Factor

Sex differences associated with primary biliary cirrhosis.

Clin Dev Immunol 2012 30;2012:610504. Epub 2012 May 30.

Institute of Liver Studies, King's College London School of Medicine, Denmark Hill Campus, London SE59PJ, UK.

View Article
October 2012
15 Reads
8 PubMed Central Citations(source)
2.930 Impact Factor

Role for mycobacterial infection in pathogenesis of primary biliary cirrhosis?

World J Gastroenterol 2012 Sep;18(35):4855-65

Institute of Liver Studies and Liver Unit, King's College London School of Medicine at King's College Hospital and Kings College Hospital NHS Trust Foundation Trust, London, United Kingdom.

View Article
September 2012
13 Reads
2 PubMed Central Citations(source)
2.370 Impact Factor

[Acute Alcoholic Hepatitis]. | Información al paciente. Hepatitis aguda alcohólica.

Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva

http://www.scopus.com/inward/record.url?eid=2-s2.0-84864302646&partnerID=MN8TOARS

View Article
2011
1 Read

Effects of bilirubin and sera from jaundiced patients on osteoblasts: contribution to the development of osteoporosis in liver diseases.

Hepatology 2011 Dec;54(6):2104-13

Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d’Investigacions Biome`diques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.

View Article
December 2011
10 Reads
6 PubMed Central Citations(source)
11.050 Impact Factor

Proteomic analysis of polypeptides captured from blood during extracorporeal albumin dialysis in patients with cholestasis and resistant pruritus.

PLoS One 2011 14;6(7):e21850. Epub 2011 Jul 14.

CSIC/UAB Proteomics Laboratory, Instituto de Investigaciones Biomédicas de Barcelona-Consejo Superior de Investigaciones Científicas/Institut d'investigacions Biomèdiques August Pi i Sunyer, Bellaterra, Spain.

View Article
November 2011
14 Reads
1 PubMed Central Citation(source)
3.230 Impact Factor

[Acute Alcoholic Hepatitis].

Authors:
Albert Parés

Rev Esp Enferm Dig 2011 Nov;103(11):597

Unidad de Hepatología, Hospital Clinic, IDIBAPS, CIBERehd, Universidad de Barcelona.

View Article
November 2011
1 Read
1.320 Impact Factor

Management of osteoporosis in liver disease.

Clin Res Hepatol Gastroenterol 2011 Jun 4;35(6-7):438-45. Epub 2011 May 4.

Liver Unit, Department of Rheumatology, Hospital Clínic, CIBERhed, University of Barcelona, Barcelona, Spain.

View Article
June 2011
21 Reads
5 PubMed Central Citations(source)
1.980 Impact Factor

[Primary sclerosing cholangitis: diagnosis, prognosis and treatment].

Authors:
Albert Parés

Gastroenterol Hepatol 2011 Jan 3;34(1):41-52. Epub 2010 Dec 3.

Unidad de Hepatología, Institut de Malalties Digestives, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Universidad de Barcelona, Barcelona, Spain.

View Article
January 2011
7 Reads
1 PubMed Central Citation(source)
0.830 Impact Factor

Liver and bone.

Arch Biochem Biophys 2010 Nov 9;503(1):84-94. Epub 2010 Jun 9.

Department of Rheumatology, University of Barcelona, Barcelona, Spain.

View Article
November 2010
8 Reads
6 PubMed Central Citations(source)
3.020 Impact Factor

Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers.

J Hepatol 2010 Aug 7;53(2):307-12. Epub 2010 May 7.

Liver Unit, Hospital Clinic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain.

View Article
August 2010
11 Reads
13 PubMed Central Citations(source)
11.340 Impact Factor

Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis.

Gastroenterology 2010 Jun 20;138(7):2348-56. Epub 2010 Feb 20.

Metabolic Bone Diseases Unit, Service of Rheumatology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.

View Article
June 2010
6 Reads
17 PubMed Central Citations(source)
16.720 Impact Factor

The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts.

Endocrine 2010 Apr 7;37(2):322-8. Epub 2010 Jan 7.

Metabolic Bone Diseases Unit, Department of Rheumatology, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain.

View Article
April 2010
10 Reads
3 PubMed Central Citations(source)
3.530 Impact Factor

Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure.

Crit Care 2009 28;13(1):R8. Epub 2009 Jan 28.

Liver Unit, Digestive Diseases Institute, Hospital Clínic, Centro de Investigaciones Biomédicas en Red de Enfermedades Hepáticas y Digestivas, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.

View Article
March 2010
11 Reads
6 PubMed Central Citations(source)

The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts.

Endocrine 2010 Feb 24;37(1):180-6. Epub 2009 Nov 24.

Metabolic Bone Diseases Unit, Department of Rheumatology, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain.

View Article
February 2010
6 Reads
3.530 Impact Factor

Characterization of peptides and proteins in commercial HSA solutions.

Proteomics 2010 Jan;10(2):172-81

CSIC/UAB Proteomics Laboratory, Instituto de Investigaciones Biomédicas de Barcelona-Consejo Superior de Investigaciones Científicas (IIBB-CSIC/IDIBAPS), Barcelona Autonomous University, 08193 Bellaterra, Spain.

View Article
January 2010
2 Reads
5 PubMed Central Citations(source)
3.810 Impact Factor

Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers.

Hepatology 2009 Oct;50(4):1162-8

Liver Unit, Digestive Diseases Institute, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Hospital Clínic, IDIBAPS, Barcelona, Spain.

View Article
October 2009
6 Reads
13 PubMed Central Citations(source)
11.050 Impact Factor

High osteoprotegerin serum levels in primary biliary cirrhosis are associated with disease severity but not with the mRNA gene expression in liver tissue.

J Bone Miner Metab 2009 20;27(3):347-54. Epub 2009 Feb 20.

Metabolic Bone Diseases Unit, Hospital Clínic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, IDIBAPS, University of Barcelona, Barcelona, Spain.

View Article
June 2009
28 Reads
5 PubMed Central Citations(source)
2.460 Impact Factor

[Natural history of primary biliary cirrhosis].

Authors:
Albert Parés

Gastroenterol Hepatol 2008 Oct;31(8):500-7

Unidad de Hepatología, Institut Clínic de Malalties Digestives i Metabòliques, Hospital Clínic, IDIBAPS, Barcelona, España.

View Article
October 2008
5 Reads
1 PubMed Central Citation(source)
0.830 Impact Factor

Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment.

Clin Liver Dis 2008 May;12(2):407-24; x

Liver Unit, Institute of Digestive Diseases, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi Sunyer, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain.

View Article
May 2008
5 Reads
16 PubMed Central Citations(source)
3.660 Impact Factor

Serum paraoxonase-1 in chronic alcoholics: relationship with liver disease.

Clin Biochem 2007 Jun 3;40(9-10):645-50. Epub 2007 Feb 3.

Centre de Recerca Biomèdica, Hospital Universitari de Sant Joan, Institut de Recerca en Ciències de la Salut, Reus, Spain.

View Article
June 2007
10 Reads
12 PubMed Central Citations(source)
2.230 Impact Factor

Treatment of bone disorders in liver disease.

J Hepatol 2006 Sep 7;45(3):445-53. Epub 2006 Jul 7.

Liver Unit, Digestive Diseases Institute and Metabolic Bone Diseases Unit, Department of Rheumatology Hospital Clínic, IDIBAPS, Barcelona, Spain.

View Article
September 2006
4 Reads
3 PubMed Central Citations(source)
11.340 Impact Factor

Characterization and differentiation of autoimmune versus viral liver involvement in patients with Sjögren's syndrome.

J Rheumatol 2006 Aug;33(8):1593-9

Department of Autoimmune Diseases and Hepatology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, IDIBAPS, School of Medicine, University of Barcelona, Barcelona, Spain.

View Article
August 2006
9 Reads
4 PubMed Central Citations(source)
3.190 Impact Factor

Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid.

Gastroenterology 2006 Mar;130(3):715-20

Liver Unit, Digestive Diseases Institute, Hospital Clínic, IDIBAPS, Barcelona, Spain.

View Article
March 2006
6 Reads
79 PubMed Central Citations(source)
16.720 Impact Factor

Prevalence and mechanisms of hyperhomocysteinemia in chronic alcoholics.

Alcohol Clin Exp Res 2005 Jun;29(6):1044-8

Liver Unit, Institut de Malalties Digestives i Metaboliques, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.

View Article
June 2005
6 Reads
18 PubMed Central Citations(source)
3.210 Impact Factor

Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis.

J Hepatol 2005 Apr 13;42(4):573-7. Epub 2005 Jan 13.

Metabolic Bone Diseases Unit, Service of Rheumatology, Hospital Clínic, IDIBAPS, University of Barcelona, C/Villarroel 170, 08036-Barcelona, Spain.

View Article
April 2005
4 Reads
21 PubMed Central Citations(source)
11.340 Impact Factor

Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis.

Eur J Gastroenterol Hepatol 2005 Mar;17(3):311-5

Liver Unit, Hospital Clínic, University of Barcelona, Spain.

View Article
March 2005
7 Reads
7 PubMed Central Citations(source)
2.150 Impact Factor

Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis.

Am J Gastroenterol 2004 Jun;99(6):1105-10

Liver Unit, Institut Clínic de Malalties Digestives, Hospital Clínic, Barcelona, Spain.

View Article
June 2004
5 Reads
12 PubMed Central Citations(source)
10.760 Impact Factor

Primary biliary cirrhosis specific antinuclear antibodies in patients from Spain.

Am J Gastroenterol 2004 Apr;99(4):763-4; author reply 765

View Article
April 2004
23 Reads
14 PubMed Central Citations(source)
10.760 Impact Factor

A randomized placebo controlled trial of vitamin E for alcoholic hepatitis.

J Hepatol 2004 Jan;40(1):40-6

Department of Medicine, 921 Ross Building, The Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, MD 21205, USA.

View Article
January 2004
15 Reads
37 PubMed Central Citations(source)
11.340 Impact Factor

Natural history of primary biliary cirrhosis.

Clin Liver Dis 2003 Nov;7(4):779-94

Liver Unit, Institute of Digestive Diseases, Hospital Clinic, University of Barcelona, C/Villarroel 170, 08036 Barcelona, Spain.

View Article
November 2003
2 Reads
15 PubMed Central Citations(source)
3.660 Impact Factor

Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis.

Am J Gastroenterol 2003 Oct;98(10):2268-74

Metabolic Bone Diseases Unit, Hospital Clínic, Institut d'Investigacions Mèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.

View Article
October 2003
9 Reads
14 PubMed Central Citations(source)
10.760 Impact Factor

Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis.

J Hepatol 2003 Jul;39(1):12-6

Inserm Unit 370, Faculté de Médecine Necker, 156 rue de Vaugirard, 75730 Paris Cedex 15, France.

View Article
July 2003
6 Reads
23 PubMed Central Citations(source)
11.340 Impact Factor

Expected developments in hepatology.

Best Pract Res Clin Gastroenterol 2002 Dec;16(6):957-70

Liver Unit, Hospital Clínic, Institut d'Investigaciones Biomédiques August Pi i Sunyer, University of Barcelona, Spain.

View Article
December 2002
8 Reads
2 PubMed Central Citations(source)
3.480 Impact Factor

Top co-authors

Albert Pares
Albert Pares

Hospital Clinic, University of Barcelona

57
Pietro Invernizzi
Pietro Invernizzi

Center for Autoimmune Liver Diseases

16
Raoul Poupon
Raoul Poupon

Université Pierre et Marie Curie

15
Ulrich Beuers
Ulrich Beuers

University of Amsterdam

12
Pilar Peris
Pilar Peris

University of Barcelona

11
Juan Rodes
Juan Rodes

Hospital Clínic

10
Annarosa Floreani
Annarosa Floreani

University of Padova

10
Keith Lindor
Keith Lindor

Mayo Clinic

9
Ana Monegal
Ana Monegal

University of Barcelona

9